Trial Profile
A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Cligosiban (Primary)
- Indications Premature ejaculation
- Focus Therapeutic Use
- Acronyms PEDRIX
- Sponsors Ixchelsis
- 24 Apr 2019 Status changed from active, no longer recruiting to completed.
- 20 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2017 Status changed from not yet recruiting to recruiting.